Xeligekimab, an Interleukin-17A Antagonist for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 48-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study
Xeligekimab（一种白细胞介素-17A拮抗剂）治疗中国活动性放射学轴性脊柱关节炎患者的16周和48周结果：一项III期随机、双盲、安慰剂对照研究
期刊:BioDrugs
影响因子:6.9
doi:10.1007/s40259-025-00750-0
Zhang, Shangzhu; Xu, Dong; Liu, Shengyun; Li, Shujie; Wang, Xiaoxia; Yuan, Fenghong; Gou, Wei; Xu, Baijie; Sun, Lingyun; Gu, Jieruo; Zhou, Dongmei; Li, Xiaomei; Kong, Ning; Zhao, Yi; Hao, Jie; Li, Tianwang; Fan, Xiaoyun; Shu, Qiang; Wei, Hua; Jiang, Tao; Yang, Jing; Qian, Long; Sun, Hongsheng; Cai, Xiaoyan; Jiang, Zhenyu; Yuan, Guohua; Qin, Li; Yang, Min; Xu, Jian; Fan, Wenqiang; Sun, Li; Zhang, Hua; Zhang, Chunyan; Zhang, Ning; Da, Zhanyun; Hu, Jiankang; Jin, Jingchun; Liu, Ju; Dai, Lie; Dong, Lingli; Wang, Wei; Zeng, Xiaofeng
